ERBB2 and breast cancer: The drug potently inhibits Akt phosphorylation in breast cancers and inhibits the proliferation of breast tumors with PI3K mutation and/or HER2 amplification but is ineffective in tumors in which PI3K and PTEN are wild-type and HER2 is expressed at normal levels.